AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Treatment of obesity through the inhibition of CaMKII

Summary

During nutrient deprivation, the liver produces glucose through a process known as hepatic glucose production (HGP). Excessive glucose production via HGP is thought to play a role in the high blood glucose levels observed in patients suffering from obesity and type II diabetes. The enzyme CaMKII, which has previously been linked to Alzheimer’s disease and heart arrhythmia, has been shown to play a role in the signaling pathway that causes HGP. This technology provides a method to treat obesity and related metabolic disorders by reducing the activity of CaMKII, and consequently, HGP and blood glucose levels.

Technology Benefits

Unique therapeutic target that is distinct from currently marketed medicationsCan be used in addition to other obesity and diabetic treatmentsWell characterized animal models Patent Information:Patent Pending (US 20140314789)Tech Ventures Reference: IR CU12060

Technology Application

Development of drugs that inhibit CaMKII to treat obesity and associated metabolic disorders (e.g. type II diabetes)Target for treatment of heart arrhythmiasWeight loss supplement in addition to diet and exercise

Detailed Technology Description

None

Country/Region

USA

For more information, please click Here